AR055107A1 - Furoato de n-{2-[((2s)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil} acetamida,composiciones farmaceuticas que los contienen y usos para tratar afecciones o enfermedades donde actuan como moduladores del receptor de quimioquina 1(ccr1) - Google Patents

Furoato de n-{2-[((2s)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil} acetamida,composiciones farmaceuticas que los contienen y usos para tratar afecciones o enfermedades donde actuan como moduladores del receptor de quimioquina 1(ccr1)

Info

Publication number
AR055107A1
AR055107A1 ARP060103360A ARP060103360A AR055107A1 AR 055107 A1 AR055107 A1 AR 055107A1 AR P060103360 A ARP060103360 A AR P060103360A AR P060103360 A ARP060103360 A AR P060103360A AR 055107 A1 AR055107 A1 AR 055107A1
Authority
AR
Argentina
Prior art keywords
methylpropil
chlorobencil
hydroxi
oxi
piperidin
Prior art date
Application number
ARP060103360A
Other languages
English (en)
Inventor
Bo-Goeran Josefsson
Julien Giovannini
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708912&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055107(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR055107A1 publication Critical patent/AR055107A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Furoato de N-{2-[((2S)-3-{[1-(4-CLOROBENCIL)PIPERIDIN-4-IL]AMINO}-2-HIDROXI-2-METILPROPIL)OXI]-4-HIDROXIFENIL}ACETAMIDA, o un solvato del mismo.
ARP060103360A 2005-08-02 2006-08-02 Furoato de n-{2-[((2s)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil} acetamida,composiciones farmaceuticas que los contienen y usos para tratar afecciones o enfermedades donde actuan como moduladores del receptor de quimioquina 1(ccr1) AR055107A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0501770 2005-08-02

Publications (1)

Publication Number Publication Date
AR055107A1 true AR055107A1 (es) 2007-08-08

Family

ID=37708912

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103360A AR055107A1 (es) 2005-08-02 2006-08-02 Furoato de n-{2-[((2s)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil} acetamida,composiciones farmaceuticas que los contienen y usos para tratar afecciones o enfermedades donde actuan como moduladores del receptor de quimioquina 1(ccr1)

Country Status (16)

Country Link
US (1) US20080280951A1 (es)
EP (1) EP1922305A1 (es)
JP (1) JP2009503065A (es)
KR (1) KR20080032144A (es)
CN (1) CN101238102A (es)
AR (1) AR055107A1 (es)
AU (1) AU2006276345A1 (es)
BR (1) BRPI0614432A2 (es)
CA (1) CA2617404A1 (es)
IL (1) IL188481A0 (es)
MX (1) MX2008001112A (es)
NO (1) NO20081081L (es)
TW (1) TW200738635A (es)
UY (1) UY29712A1 (es)
WO (1) WO2007015667A1 (es)
ZA (1) ZA200800522B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008100202A1 (en) * 2007-02-14 2008-08-21 Astrazeneca Ab A 2-f luorobenzoate salt and a 2, 6-dif luorobenzoate salt of n-{5-chloro-2- [ ( (2s) -3-{ [1- (4-chlorobenzyl)piperidin-4- yl ] amino } - 2 - hydroxy- 2 -me t hylpr opyl ) oxy] - 4 - hydroxyphenyl } acetamide
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
AU2008356409B2 (en) 2008-05-13 2012-01-19 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131290B1 (en) * 1998-11-20 2008-02-20 F. Hoffmann-La Roche Ag Piperidine ccr-3 receptor antagonists
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
GB0021670D0 (en) * 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
SE0104251D0 (sv) * 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
UY29712A1 (es) 2007-02-28
CN101238102A (zh) 2008-08-06
WO2007015667A1 (en) 2007-02-08
IL188481A0 (en) 2008-04-13
MX2008001112A (es) 2008-03-11
AU2006276345A1 (en) 2007-02-08
JP2009503065A (ja) 2009-01-29
TW200738635A (en) 2007-10-16
US20080280951A1 (en) 2008-11-13
NO20081081L (no) 2008-02-29
EP1922305A1 (en) 2008-05-21
ZA200800522B (en) 2008-12-31
KR20080032144A (ko) 2008-04-14
BRPI0614432A2 (pt) 2011-03-29
CA2617404A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
BRPI0918868B8 (pt) compostos moduladores do receptor de nmda e composições compreendendo os mesmos
BRPI0709581A8 (pt) compostos de bicicloeteroarila como moduladores de px27 e seu uso
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
CR8778A (es) Revestimientos de azucar y metodos para estos
CL2008002768A1 (es) Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades.
BRPI0607897A2 (pt) compostos oxindol e sua utilização como agentes terapêuticos
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
CY1112721T1 (el) Νεοι συνδετες που διαμορφωνουν τους υποδοχεις rαr, και χρηση αυτων στην ιατρικη για τον ανθρωπο και στα καλλυντικα
CR10900A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos
CL2008001465A1 (es) Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer.
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
CR9469A (es) Derivados de urea, metodos para su fabricacion y usos para los mismos
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".

Legal Events

Date Code Title Description
FA Abandonment or withdrawal